Palmitoylethanolamide

Dec 02, 2019

Therapix Biosciences Announces the Continued Development of THX-210 ("RESPECTRUM") Cannabinoids Based Treatment for Autism Spectrum Disorder

Nov 13, 2019

Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program

Oct 17, 2019

Metagenics Releases Hemp Advantage(TM) Plus

Oct 15, 2019

Therapix Biosciences Announces Positive Data From Recent Pre-clinical Study for New Drug Candidate THX-210

Jul 31, 2019

Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide(TM)), a Non-Opiate Based Pain Management Supplement

May 29, 2019

Therapix Biosciences Issues Shareholder Update Letter

Mar 07, 2019

Life Extension Launches PEA Discomfort Relief Supplement

Mar 20, 2018

Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain

Feb 07, 2018

Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected

Dec 04, 2017

Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program

Dec 04, 2017

Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program